Abstract
The optimal management of Lyme disease involves the use of antibacterials as prophylaxis and to treat manifestations of the disease. Treatment guidelines offer somewhat conflicting recommendations due to the absence of strong and compelling clinical evidence regarding the treatment of this disease. Ultimate treatment decisions should be made by the physician based on clinical judgement and the individual patient’s circumstances.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Godar DA, Laniosz V, Wetter DA. Lyme disease update for the general dermatologist. Am J Clin Dermatol. 2015;16(1):5–18.
Rizzoli A, Hauffe HC, Carpi G, et al. Lyme borreliosis in Europe. Euro Surveill. 2011;16(27) (pii: 19906).
Steere AC. Lyme borreliosis. In: Longo DL, Fauci AS, Kasper DL, et al., editors. Harrison’s principles of internal medicine. 18th ed. New York: McGraw Hill Medical; 2012. p. 1401–6.
Bhate C, Schwartz RA. Lyme disease: part I: advances and perspectives. J Am Acad Dermatol. 2011;64(4):619–36.
Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(9):1089–134.
Glatz M, Fingerle V, Wilske B, et al. Immunoblot analysis of the seroreactivity to recombinant Borrelia burgdorferi sensu lato antigens, including VlsE, in the long-term course of treated patients with erythemamigrans. Dermatology. 2008;216(2):93–103.
Bratton RL, Whiteside JW, Hovan MJ, et al. Diagnosis and treatment of Lyme disease. Mayo Clin Proc. 2008;83(5):566–71.
Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti Infect Ther. 2014;12(9):1103–35.
Infectious Disease Society of America. IDSA/AAN/ACR Lyme disease guideline project plan. 2015. http://www.idsociety.org. Accessed 14 Apr 2015.
Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med. 2001;345(2):79–84.
Embers ME, Narasimhan S. Vaccination against Lyme disease: past, present, and future. Front Cell Infect Microbiol. 2013;12(3):6.
Doryx® (doxycyline hyclate delayed-release tablets): US prescribing information. Rockaway: Warner Chilcott (US), LLC; 2013.
Tonks A. Lyme wars. BMJ. 2007;335(7626):910–2.
Feder HM Jr, Johnson BJB, O’Connell S, et al. A critical appraisal of “chronic Lyme disease”. N Engl J Med. 2007;357(14):1422–30.
Johnson L, Stricker RB. The Infectious Diseases Society of America Lyme guidelines: a cautionary tale about the development of clinical practice guidelines. Philos Ethics Humanit Med. 2010;5:9.
Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001;345(2):85–92.
Lantos PM, Charini WA, Medoff G, et al. Final report of the Lyme disease review panel of the Infectious Diseases Society of America. Clin Infect Dis. 2010;51(1):1–5.
Disclosure
This article was adapted from the American Journal of Clinical Dermatology 2015; 16(1):5–18 [1] by salaried employees of Adis/Springer, and was not supported by any external funding.
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Adis Medical Writers. Prevent and manage Lyme disease with antibacterials based on patient characteristics, local causative species and disease manifestations. Drugs Ther Perspect 31, 266–271 (2015). https://doi.org/10.1007/s40267-015-0221-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-015-0221-1